|
|
Article: Marillion Pharmaceuticals and Cytokine PharmaSciences Announce License Agreement for Xerostomia Treatment.
- Article from:
- Business Wire
- Article date:
- February 25, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Marillion Acquires Exclusive Worldwide Rights to Pilocarpine Buccal Insert for Xerostomia and Sjogren's Syndrome from Cytokine PharmaSciences
MALVERN, Pa. & KING OF PRUSSIA, Pa. -- Marillion Pharmaceuticals Inc and Cytokine PharmaSciences Inc (CPSI) announced today that the two companies have entered into a license agreement granting Marillion exclusive worldwide rights to develop and commercialize CPSI's Pilobuc[TM] buccal insert for the treatment of xerostomia.
Xerostomia, meaning dry mouth, is characterized by the chronic loss of salivary gland function and has been associated with various autoimmune diseases (e.g. Sjogren's syndrome), treatment with ...